文献速递牙体牙髓病

自身免疫性疾病患者根尖周炎患病率:病例对照研究

Prevalence of apical periodontitis in patients with autoimmune diseases: A case-control study.
PubMed 文献 · Int Endod J · 2023-02-22

这项病例对照研究比较了89例自身免疫性疾病患者(2145颗牙)与89例无系统性疾病对照(2329颗牙)的根尖周炎患病率。AD组根尖周炎患病率为89.9%,对照组为74.2%(OR=3.75,p=.015)。AD患者无论是否接受生物制剂治疗,根尖周炎患病率均高于对照组。

要点

  • AD患者根尖周炎患病率89.9%,对照组74.2%(OR=3.75,p=.015)。
  • RA患者根尖周炎风险最高,IBD患者风险最低。
  • 未用药或使用bDMARDs的AD患者牙齿根尖周炎风险高于对照(OR=1.42和OR=2.03,p=.010)。

核心结论

  • AD患者无论是否接受生物制剂治疗,根尖周炎患病率均高于对照组。
  • AD患者DMFT评分高于对照,且被确定为根尖周炎患病率的显著预测因素。

研究设计与样本

  • 病例对照研究,纳入89例自身免疫性疾病患者(2145颗牙)和89例无系统性疾病对照(2329颗牙)。
  • 使用全口牙全景断层片确定牙齿根尖周状态。
  • 采用卡方检验和逻辑回归分析评估AD与AP的相关性,p<.05为统计学显著。

主要发现

  • AP患病率在AD患者为89.9%,在对照组为74.2%(OR=3.75,p=.015)。
  • DMFT评分在AD组显著更高(p=.004)。
  • RA患者受AP影响的风险最高,IBD患者风险最低。
  • 未用药的AD患者牙齿AP风险高于对照(OR=1.42,p=.010)。
  • 使用bDMARDs的AD患者牙齿AP风险高于对照(OR=2.03,p=.010)。

关键数值与推荐

  • AP患病率:AD组89.9% vs 对照组74.2%(OR=3.75,p=.015)。
  • 未用药AD患者牙齿AP风险 vs 对照:OR=1.42(p=.010)。
  • 使用bDMARDs的AD患者牙齿AP风险 vs 对照:OR=2.03(p=.010)。
  • DMFT评分AD组显著高于对照组(p=.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The purpose of this case-control study was to compare the prevalence of apical periodontitis (AP) in patients affected by autoimmune disorders (AD) (inflammatory bowel disease [IBD], rheumatoid arthritis [RA] and psoriasis [Ps]) with the prevalence of AP in subjects without AD. The prevalences of AP in patients taking biologic medications, conventional medications and no medication were also compared. METHODOLOGY: Eighty-nine patients (2145 teeth) with AD were investigated and the control group included 89 patients (2329 teeth) with no systemic diseases. Full dental panoramic tomograms were used to determine the periapical status of the teeth. Additional variables investigated included patient's socio-demographic characteristics, medications taken by AD patients, the decayed, missing and filled teeth (DMFT) index. The chi-square test and logistic regression analysis were used to evaluate the correlation between AD and AP. p-Values lower than .05 were considered to be statistically significant. RESULTS: The prevalence of AP was 89.9% in AD patients and 74.2% in control subjects (odds ratio [OR] = 3.75, p = .015). The DMFT score was found to be significantly higher in the AD group (p = .004). Patients with RA had the highest risk of being affected by AP, whereas those with IBD had the lowest risk. Multiple binary logistic regression analysis indicated that the teeth of AD patients who were not taking any medication or were being treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) had a higher risk of being affected by AP than did the teeth of the control subjects (OR = 1.42 and OR = 2.03, respectively; p = .010). The teeth of patients taking conventional DMARDs (cDMARDs) were less affected by AP compared with those of patients taking bDMARDs. CONCLUSIONS: Patients with AD, whether treated or not with biologic medications, showed a higher prevalence of AP than did those in the control group. The DMFT index score, which was higher in AD patients compared with controls was identified as a significant predictor of AP prevalence.

来源:Int Endod J,查看原文。版权归原作者所有。

引用

  1. Allihaibi M, Niazi SA, Farzadi S, et al. Prevalence of apical periodontitis in patients with autoimmune diseases: A case-control study. Int Endod J. 2023. PMID: 36747086. doi:10.1111/iej.13902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。